Loading…
Please register to continue your trial period!
meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.
Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.
Start your free trial and transform your understanding of the gut microbiota today!
In the context of Anti-PD-1 Antibodies / PD-1 Inhibitors & Head & Neck squamous cell carcinoma (HNSCC), two phase III clinical trials, known as NCT02105636 (CheckMate 141) and NCT02252042 (KEYNOTE 040), have independently shown that overall survival (OS) in patients with recurrent and/or metastatic Head & Neck squamous cell carcinoma (HNSCC), who have not responded to platinum-based therapy, can be enhanced with anti-PD1 monotherapy. The use of nivolumab or pembrolizumab in these R/M HNSCC patients resulted in improved …